Bevacizumab Injection for Recurrent Pterygium

CompletedOBSERVATIONAL
Enrollment

38

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Recurrent Pterygium
Interventions
DRUG

Bevacizumab

DRUG

Medical Treatment

Care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.

DRUG

Medical Treatment

Care treatment included topical eyedrops of 0.3% tobramycin and 0.1% dexamethasone (Trazidex, Laboratorios Sophia) three times daily, and 0.5 carboxymethylcellulose lubricating eye drops (Refresh-Tears, Allergan, Irving, California, USA). Topical antibiotics and corticosteroids were tapered and discontinued after two weeks.

PROCEDURE

Argon laser treatment

Trial Locations (1)

06800

Institute of Ophthalmology, Conde de Valenciana Foundation, Mexico City

All Listed Sponsors
collaborator

National Council of Science and Technology, Mexico

OTHER

lead

Instituto de Oftalmología Fundación Conde de Valenciana

OTHER

NCT02007174 - Bevacizumab Injection for Recurrent Pterygium | Biotech Hunter | Biotech Hunter